Benzinga | Jan 21, 2022 06:55AM EST

B of A Securities Upgrades Moderna to Neutral, Raises Price Target to $180

B of A Securities analyst Geoff Meacham upgrades Moderna (NASDAQ:MRNA) from Underperform to Neutral and raises the price target from $135 to $180.